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Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase
of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/
10.1111/bph.13351/full. Other ion channels are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion
channels, voltage-gated ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best
available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets.
It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented
in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification
and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable,
point-in-time record that will survive database updates.
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Aquaporins
Other ion channels! Aquaporins
Overview: Aquaporins and aquaglyceroporins are membrane
channels that allow the permeation of water and certain other
small solutes across the cell membrane. Since the isolation and
cloning of the first aquaporin (AQP1) [77], 12 additional members
of the family have been identified, although little is known about
the functional properties of two of these (AQP11; Q8NBQ7 and
AQP12A; Q8IXF9). The other 11 aquaporins can be divided into
two families (aquaporins and aquaglyceroporins) depending on
whether they are permeable to glycerol [41]. One or more mem-
bers of this family of proteins have been found to be expressed in
almost all tissues of the body. Individual AQP subunits have six
transmembrane domains with an inverted symmetry between the
first three and last three domains [15]. Functional AQPs exist as
tetramers but, unusually, each subunit contains a separate pore,
so each channel has four pores.
Nomenclature AQP0 AQP1 AQP2 AQP3 AQP4 AQP5
HGNC, UniProt MIP, P30301 AQP1, P29972 AQP2, P41181 AQP3, Q92482 AQP4, P55087 AQP5, P55064
Permeability water (low) water (high) water (high) water (high), glycerol water (high) water (high)
Endogenous
activators
– cyclic GMP – – – –
Inhibitors Hg2+ Ag+, Hg2+,
tetraethylammonium
Hg2+ Hg2+ (also inhibited
by acid pH)
– Hg2+
Comments – – – AQP3 is also inhibited
by acid pH
AQP4 is inhibited
by PKC activation
–
Nomenclature AQP6 AQP7 AQP8 AQP9 AQP10
HGNC, UniProt AQP6, Q13520 AQP7, O14520 AQP8, O94778 AQP9, O43315 AQP10, Q96PS8
Permeability water (low), anions water (high), glycerol water (high) water (low), glycerol water (low), glycerol
Inhibitors Hg2+ Hg2+ Hg2+ Hg2+, phloretin Hg2+
Comments AQP6 is an intracellular channel
permeable to anions as well as
water [106]
– – – –
Further Reading
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Neurosci. 4: 991-1001 [PMID:14682361]
Carbrey JM et al. (2009) Discovery of the aquaporins and development of the field. Handb Exp
Pharmacol 3-28 [PMID:19096770]
Castle NA. (2005) Aquaporins as targets for drug discovery. Drug Discov. Today 10: 485-93
[PMID:15809194]
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Chloride channels
Other ion channels! Chloride channels
Overview: Chloride channels are a functionally and structurally
diverse group of anion selective channels involved in various
processes including the regulation of the excitability of neu-
rones, skeletal, cardiac and smooth muscle, cell volume regula-
tion, transepithelial salt transport, the acidification of internal and
extracellular compartments, the cell cycle and apoptosis (reviewed
in [22]). Excluding the transmitter-gated GABAA and glycine re-
ceptors (see separate tables), well characterised chloride channels
can be classified as certain members of the voltage-sensitive ClC
subfamily, calcium-activated channels, high (maxi) conductance
channels, the cystic fibrosis transmembrane conductance regula-
tor (CFTR) and volume regulated channels [101]. No official rec-
ommendation exists regarding the classification of chloride chan-
nels. Functional chloride channels that have been cloned from,
or characterised within, mammalian tissues are listed with the ex-
ception of several classes of intracellular channels (e.g. CLIC) that
are reviewed in [26].
ClC family
Other ion channels! Chloride channels! ClC family
Overview: The mammalian ClC family (reviewed in [2, 16, 22,
24, 40]) contains 9 members that fall, on the basis of sequence
homology, into three groups; ClC-1, ClC-2, hClC-Ka (rClC-K1)
and hClC-Kb (rClC-K2); ClC-3 to ClC-5, and ClC-6 and -7. ClC-1
and ClC-2 are plasma membrane chloride channels. ClC-Ka and
ClC-Kb are also plasma membrane channels (largely expressed in
the kidney and inner ear) when associated with barttin (BSND,
Q8WZ55), a 320 amino acid 2TM protein [27]. The localisation
of the remaining members of the ClC family is likely to be pre-
dominantly intracellular in vivo, although they may traffic to the
plasma membrane in overexpression systems. Numerous recent
reports indicate that ClC-4, ClC-5, ClC-6 and ClC-7 (and by in-
ference ClC-3) function as Cl-/H+ antiporters (secondary active
transport), rather than classical Cl- channels [34, 48, 62, 73, 87];
reviewed in [2, 79]). It has recently been reported that the activity
of ClC-5 as a Cl-/H+ exchanger is important for renal endocytosis
[64]. Alternative splicing increases the structural diversity within
the ClC family. The crystal structure of two bacterial ClC proteins
has been described [25] and a eukaryotic ClC transporter (Cm-
CLC) has recently been described at 3.5 Å resolution [30]. Each
ClC subunit, with a complex topology of 18 intramembrane seg-
ments, contributes a single pore to a dimeric ‘double-barrelled’
ClC channel that contains two independently gated pores, con-
firming the predictions of previous functional and structural in-
vestigations (reviewed in [16, 24, 40, 79]). As found for ClC-4,
ClC-5, ClC-6 and ClC-7, the prokaryotic ClC homologue (ClC-
ec1) and CmCLC function as H+/Cl antiporters, rather than as
ion channels [1, 30]. The generation of monomers from dimeric
ClC-ec1 has firmly established that each ClC subunit is a func-
tional unit for transport and that cross-subunit interaction is not
required for Cl-/H+ exchange in ClC transporters [81].
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Nomenclature ClC-1 ClC-2 ClC-Ka ClC-Kb
HGNC, UniProt CLCN1, P35523 CLCN2, P51788 CLCNKA, P51800 CLCNKB, P51801
Functional Characteristics γ = 1-1.5 pS; voltage-activated
(depolarization) (by fast gating
of single protopores and a slower
common gate allowing both
pores to open simultaneously);
inwardly rectifying; incomplete
deactivation upon repolarization,
ATP binding to cytoplasmic
cystathionine β-synthetase
related (CBS) domains inhibits
ClC-1 (by closure of the common
gate), depending on its redox
status
γ = 2-3 pS; voltage-activated by
membrane hyperpolarization by
fast protopore and slow
cooperative gating; channels
only open negative to ECl
resulting in steady-state inward
rectification; voltage dependence
modulated by permeant anions;
activated by cell swelling, PKA,
and weak extracellular acidosis;
potentiated by SGK1; inhibited
by phosphorylation by
p34(cdc2)/cyclin B; cell surface
expression and activity increased
by association with Hsp90
γ = 26 pS; linear current-voltage
relationship except at very
negative potentials; no time
dependence; inhibited by
extracellular protons (pK = 7.1);
potentiated by extracellular Ca2+
Bidirectional rectification; no
time dependence; inhibited by
extracellular protons; potentiated
by extracellular Ca2+
Endogenous activators – arachidonic acid – –
Activators – lubiprostone, omeprazole niflumic acid (pEC50 3–5) niflumic acid (pEC50 3–5)
Channel blockers 9-anthroic acid, S-(-)CPB,
S-(-)CPP, Cd2+, Zn2+,
fenofibric acid, niflumic acid
GaTx2 (pKd 10.8) [voltage
dependent -100mV], Cd2+,
NPPB, Zn2+,
diphenylamine-2-carboxylic acid
3-phenyl-CPP, DIDS,
niflumic acid
3-phenyl-CPP, DIDS
Comments CIC-1 is constitutively active CIC-2 is also activated by
amidation
CIC-Ka is constitutively active
(when co-expressed with
barttin), and can be blocked by
benzofuran derivatives
CIC-Kb is constitutively active
(when co-expressed with
barttin), and can be blocked by
benzofuran derivatives
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Nomenclature ClC-3 ClC-4 ClC-5 ClC-6 ClC-7
HGNC, UniProt CLCN3, P51790 CLCN4, P51793 CLCN5, P51795 CLCN6, P51797 CLCN7, P51798
Functional Characteristics Cl-/H+ antiporter [58];
pronounced outward
rectification; slow
activation, fast
deactivation; activity
enhanced by CaM
kinase II; inhibited by
intracellular
Ins(3,4,5,6)P4 and
extracellular acidosis
Cl-/H+ antiporter
(2Cl-:1H+) [3, 73, 87];
extreme outward
rectification;
voltage-dependent
gating with midpoint of
activation at +73 mV
[67]; rapid activation
and deactivation;
inhibited by extracellular
acidosis; non-hydrolytic
nucleotide binding
required for full activity
Cl-/H+ antiporter
(2Cl-:1H+) [73, 87, 94,
109]; extreme outward
rectification;
voltage-dependent
gating with midpoint of
activation of 116.0 mV;
rapid activation and
deactivation;
potentiated and
inhibited by intracellular
and extracellular
acidosis, respectively;
ATP binding to
cytoplasmic
cystathionine
β-synthetase related
(CBS) domains activates
ClC-5
Cl-/H+ antiporter
(2Cl-:1H+) [62];
outward rectification,
rapid activation and
deactivation
Cl-/H+ antiporter
(2Cl-:1H+) [34, 48, 90];
strong outward
rectification;
voltage-dependent
gating with a threshold
more positive than + 20
mV; very slow activation
and deactivation
Channel blockers phloretin (pIC50 4.5) Zn
2+ (pIC50 4.3) [68],
Cd2+ (pIC50 4.2) [68]
– DIDS (pIC50 3) DIDS (pIC50 4.4) [90],
NS5818 (pIC50 4.3)
[90], NPPB (pIC50 3.8)
[90]
Comments insensitive to the
channel blockers DIDS,
NPPB and tamoxifen (10
M)
– insensitive to the
channel blockers DIDS
(1 mM),
diphenylamine-2-carboxylic acid
(1 mM), 9-anthroic acid
(2 mM), NPPB (0.5 mM)
and niflumic acid (1
mM)
– active when
co-expressed with
Ostm1
Comments: ClC channels display the permeability sequence Cl-
> Br- > I- (at physiological pH). ClC-1 has significant opening
probability at resting membrane potential, accounting for 75%
of the membrane conductance at rest in skeletal muscle, and is
important for stabilization of the membrane potential. S-(-)CPP,
9-anthroic acid and niflumic acid act intracellularly and exhibit a
strongly voltage-dependent block with strong inhibition at nega-
tive voltages and relief of block at depolarized potentials ([49] and
reviewed in [78]). Inhibition of ClC-2 by the peptide GaTx2, from
Leiurus quinquestriatus herbareus venom, is likely to occur through
inhibition of channel gating, rather than direct open channel
blockade [98]. Although ClC-2 can be activated by cell swelling,
it does not correspond to the VRAC channel (see below). Alter-
native potential physiological functions for ClC-2 are reviewed in
[76]. Functional expression of humanClC-Ka and ClC-Kb requires
the presence of barttin [27, 88] reviewed in [29]. The properties of
ClC-Ka/barttin and ClC-Kb/barttin tabulated are those observed
in mammalian expression systems: in oocytes the channels dis-
play time- and voltage-dependent gating. The rodent homologue
(ClC-K1) of ClC-Ka demonstrates limited expression as a homo-
mer, but its function is enhanced by barttin which increases both
channel opening probablility in the physiological range of poten-
tials [27, 32, 88] reviewed in [29]). ClC-Ka is approximately 5 to
6-fold more sensitive to block by 3-phenyl-CPP and DIDS than
ClC-Kb, while newly synthesized benzofuran derivatives showed
the same blocking affinity (<10 M) on both CLC-K isoforms [50].
The biophysical and pharmacological properties of ClC-3, and the
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relationship of the protein to the endogenous volume-regulated
anion channel(s) VRAC [4, 36] are controversial and further com-
plicated by the possibility that ClC-3 may function as both a
Cl-/H+ exchanger and an ion channel [4, 73, 104]. The functional
properties tabulated are those most consistent with the close struc-
tural relationship between ClC-3, ClC-4 and ClC-5. Activation of
heterologously expressed ClC-3 by cell swelling in response to hy-
potonic solutions is disputed, as aremany other aspects of its regu-
lation. Dependent upon the predominant extracellular anion (e.g.
SCN- versus Cl-), CIC-4 can operate in two transport modes: a slip-
page mode in which behaves as an ion channel and an exchanger
mode in which unitary transport rate is 10-fold lower [3]. Similar
findings have been made for ClC-5 [108]. ClC-7 associates with a
β subunit, Ostm1, which increases the stability of the former [45]
and is essential for its function [48].
CFTR
Other ion channels! Chloride channels! CFTR
Overview: CFTR, a 12TM, ABC transporter-type protein, is a
cAMP-regulated epithelial cell membrane Cl- channel involved in
normal fluid transport across various epithelia. Of the 1700 muta-
tions identified in CFTR, the most common is the deletion mutant
1F508 (a class 2 mutation) which results in impaired trafficking
of CFTR and reduces its incorporation into the plasma membrane
causing cystic fibrosis (reviewed in [18]). Channels carrying the
1F508 mutation that do traffic to the plasma membrane demon-
strate gating defects. Thus, pharmacological restoration of the
function of the 1F508 mutant would require a compound that
embodies ‘corrector’ (i.e. facilitates folding and trafficking to the
cell surface) and ‘potentiator’ (i.e. promotes opening of channels
at the cell surface) activities [18]. In addition to acting as an an-
ion channel per se, CFTR may act as a regulator of several other
conductances including inhibition of the epithelial Na channel
(ENaC), calcium activated chloride channels (CaCC) and volume
regulated anion channel (VRAC), activation of the outwardly rec-
tifying chloride channel (ORCC), and enhancement of the sulpho-
nylurea sensitivity of the renal outer medullary potassium channel
(ROMK2), (reviewed in [63]). CFTR also regulates TRPV4, which
provides the Ca2+ signal for regulatory volume decrease in airway
epithelia [6]. The activities of CFTR and the chloride-bicarbonate
exchangers SLC26A3 (DRA) and SLC26A6 (PAT1) are mutually en-
hanced by a physical association between the regulatory (R) do-
main of CFTR and the STAS domain of the SCL26 transporters, an
effect facilitated by PKA-mediated phosphorylation of the R do-
main of CFTR [42].
Nomenclature CFTR
HGNC, UniProt CFTR, P13569
Functional Characteristics γ = 6-10 pS; permeability sequence = Br-  Cl- > I- > F-, (PI/PCl = 0.1-0.85); slight outward rectification; phosphorylation necessary for activation by ATP binding
at binding nucleotide binding domains (NBD)1 and 2; positively regulated by PKC and PKGII (tissue specific); regulated by several interacting proteins including
syntaxin 1A, Munc18 and PDZ domain proteins such as NHERF (EBP50) and CAP70
Activators felodipine (Potentiation) (pKi 8.4) [71], CBIQ (Potentiation), NS004 (Potentiation), UCCF-029 (Potentiation), UCCF-339 (Potentiation), UCCF-853 (Potentiation),
apigenin (Potentiation), capsaicin (Potentiation), genistein (Potentiation), ivacaftor (Potentiation), nimodipine (Potentiation), phenylglycine-01 (Potentiation),
sulfonamide-01 (Potentiation)
Selective inhibitors crofelemer (pIC50 5.2) [99]
Channel blockers glibenclamide (pKi 4.7) [91], intracellular CFTRinh-172 (intracellular application prolongs mean closed time), GaTx1, extracellular GlyH-101
Comments UCCF-339, UCCF-029, apigenin and genistein are examples of flavones. UCCF-853 and NS004 are examples of benzimidazolones. CBIQ is an example of a
benzoquinoline. felodipine and nimodipine are examples of 1,4-dihydropyridines. phenylglycine-01 is an example of a phenylglycine. sulfonamide-01 is an
example of a sulfonamide. Malonic acid hydrazide conjugates are also CFTR channel blockers (see Verkman and Galietta, 2009 [101])
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Comments: In addition to the agents listed in the table, the novel
small molecule, ataluren, induces translational read through of
nonsense mutations in CFTR (reviewed in [93]). Corrector com-
pounds that aid the folding of DF508CFTR to increase the amount
of protein expressed and potentially delivered to the cell surface
include VX-532 (which is also a potentiator), VRT-325, KM11060,
Corr-3a and Corr-4a see [101] for details and structures of Corr-
3a and Corr-4a). Inhibition of CFTR by intracellular applica-
tion of the peptide GaTx1, from Leiurus quinquestriatus herbareus
venom, occurs preferentially for the closed state of the channel
[33]. CFTR contains two cytoplasmic nucleotide binding domains
(NBDs) that bind ATP. A single open-closing cycle is hypothesised
to involve, in sequence: binding of ATP at the N-terminal NBD1,
ATP binding to the C-terminal NBD2 leading to the formation of
an intramolecular NBD1-NBD2 dimer associated with the open
state, and subsequent ATP hydrolysis at NBD2 facilitating disso-
ciation of the dimer and channel closing, and the initiation of a
new gating cycle [5, 59]. Phosphorylation by PKA at sites within
a cytoplasmic regulatory (R) domain facilitates the interaction of
the two NBD domains. PKC (and PKGII within intestinal epithe-
lial cells via guanylinstimulated cyclic GMP formation) positively
regulate CFTR activity.
Calcium activated chloride channel
Other ion channels! Chloride channels! Calcium activated chloride channel
Overview: Chloride channels activated by intracellular calcium
(CaCC) are widely expressed in excitable and non-excitable cells
where they perform diverse functions [37]. The molecular nature
of CaCC has been uncertain with both CLCA, TWEETY andBEST
genes having been considered as likely candidates [22, 38, 51]. It is
now accepted that CLCA expression products are unlikely to form
channels per se and probably function as cell adhesion proteins,
or are secreted [70]. Similarly, TWEETY gene products do not re-
capictulate the properties of endogenous CaCC. The bestrophins
encoded by genes BEST1-4 have a topology more consistent with
ion channels [38] and form chloride channels that are activated
by physiological concentrations of Ca2+, but whether such acti-
vation is direct is not known [38]. However, currents generated by
bestrophin over-expression do not resemble native CaCC currents.
The evidence for and against bestrophin proteins forming CaCC is
critically reviewed by Duran et al. [22]. Recently, a new gene fam-
ily, TMEM16 (anoctamin) consisting of 10 members (TMEM16A-
K; anoctamin 1-10) has been identified and there is firm evidence
that some of these members form chloride channels [21, 43].
TMEM16A (anoctamin 1; Ano 1) produces Ca2+-activated Cl- cur-
rents with kinetics similar to native CaCC currents recorded from
different cell types [14, 82, 89, 105]. Knockdown of TMEM16A
greatly reduces currents mediated by calcium-activated chloride
channels in submandibular gland cells [105] and smooth muscle
cells from pulmonary artery [55]. In TMEM16A(-/-) mice secretion
of Ca2+-dependent Cl- secretion by several epithelia is reduced
[69, 82]. Alternative splicing regulates the voltage- and Ca2+- de-
pendence of TMEM16A and such processing may be tissue-specific
manner and thus contribute to functional diversity [31]. There
are also reports that TMEM16B (anoctamin 2; Ano 2) supports
CaCC activity (e.g.[74]) and in TMEM16B(-/-) mice Ca-activated
Cl- currents in the main olfactory epithelium (MOE) and in the
vomeronasal organ are virtually absent[11] .
Nomenclature CaCC
HGNC, UniProt ANO1, Q5XXA6
Functional Characteristics γ = 0.5-5 pS; permeability sequence, SCN- > NO3
-
> I- > Br- > Cl- > F-; relative permeability of SCN-:Cl- 8. I-:Cl- 3, aspartate:Cl- 0.15, outward
rectification (decreased by increasing [Ca2+]i); sensitivity to activation by [Ca
2+]i decreased at hyperpolarized potentials; slow activation at positive
potentials (accelerated by increasing [Ca2+]i); rapid deactivation at negative potentials, deactivation kinetics modulated by anions binding to an external
site; modulated by redox status
Endogenous activators intracellular Ca2+
Selective inhibitors crofelemer (pIC50 5.2) [99]
Endogenous channel blockers Ins(3,4,5,6)P4
Channel blockers 9-anthroic acid, DCDPC, DIDS, NPPB, SITS, flufenamic acid, fluoxetine, mibefradil, niflumic acid, tannic acid
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Comments: Blockade of ICl(Ca) by niflumic acid, DIDS and
9-anthroic acid is voltage-dependent whereas block by NPPB is
voltage-independent [37]. Extracellular niflumic acid; DCDPC
and 9-anthroic acid (but not DIDS) exert a complex effect upon
ICl(Ca) in vascular smooth muscle, enhancing and inhibiting in-
wardly and outwardly directed currents in a manner dependent
upon [Ca2+]i (see [46] for summary). Considerable crossover in
pharmacology with large conductance Ca2+-activated K+ chan-
nels also exists (see [35] for overview). Two novel compounds,
CaCCinh-A01 and CaCCinh-B01 have recently been identified
as blockers of calcium-activated chloride channels in T84 human
intestinal epithelial cells [19] for structures). Significantly, other
novel compounds totally block currents mediated by TMEM116A,
but have only a modest effect upon total current mediated by
CaCC native to T84 cells or human bronchial epithelial cells, sug-
gesting that TMEM16A is not the predominant CaCC in such cells
[61]. CaMKII modulates CaCC in a tissue dependent manner (re-
viewed by [37, 46]). CaMKII inhibitors block activation of ICl(Ca)
in T84 cells but have no effect in parotid acinar cells. In tracheal
and arterial smooth muscle cells, but not portal vein myocytes,
inhibition of CaMKII reduces inactivation of ICl(Ca). Intracellu-
lar Ins(3,4,5,6)P4 may act as an endogenous negative regulator
of CaCC channels activated by Ca2+, or CaMKII. Smooth mus-
cle CaCC are also regulated positively by Ca2+-dependent phos-
phatase, calcineurin (see [46] for summary).
Maxi chloride channel
Other ion channels! Chloride channels!Maxi chloride channel
Overview: Maxi Cl- channels are high conductance, anion se-
lective, channels initially characterised in skeletal muscle and
subsequently found in many cell types including neurones, glia,
cardiac muscle, lymphocytes, secreting and absorbing epithelia,
macula densa cells of the kidney and human placenta syncytiotro-
phoblasts [84]. The physiological significance of the maxi Cl-
channel is uncertain, but roles in cell volume regulation and apop-
tosis have been claimed. Evidence suggests a role for maxi Cl-
channels as a conductive pathway in the swelling-induced release
of ATP from mouse mammary C127i cells that may be important
for autocrine and paracrine signalling by purines [23, 83]. A sim-
ilar channel mediates ATP release from macula densa cells within
the thick ascending of the loop of Henle in response to changes in
luminal NaCl concentration [9]. A family of human high conduc-
tance Cl- channels (TTYH1-3) that resemble Maxi Cl- channels
has been cloned [95], but alternatively, Maxi Cl- channels have
also been suggested to correspond to the voltage-dependent an-
ion channel, VDAC, expressed at the plasma membrane [7, 65].
Nomenclature Maxi Cl-
Functional Characteristics γ = 280-430 pS (main state);
permeability sequence, I > Br > Cl > F > gluconate (PCIPCl = 1.5);
ATP is a voltage dependent permeant blocker of single channel activity (PATP/PCl = 0.08-0.1); channel activity increased by patch-excision;
channel opening probability (at steady-state) maximal within approximately  20 mV of 0 mV, opening probability decreased at more negative
and (commonly) positive potentials yielding a bell-shaped curve; channel conductance and opening probability regulated by annexin 6
Activators cytosolic GTPγS, extracellular chlorpromazine, extracellular tamoxifen, extracellular toremifene, extracellular triflupromazine
Endogenous channel blockers intracellular arachidonic acid
Channel blockers DIDS (pIC50 4.4) [90], extracellular Zn
2+ (pIC50 4.3) [68], NPPB (pIC50 3.8) [90], extracellular Gd
3+, SITS, diphenylamine-2-carboxylic acid
Comments Maxi Cl- is also activated by G protein-coupled receptors and cell swelling. tamoxifen and toremifene are examples of triphenylethylene
anti-oestrogens
Comments: Differing ionic conditions may contribute to vari-
able estimates of γ reported in the literature. Inhibition by
arachidonic acid (and cis-unsaturated fatty acids) is voltage-
independent, occurs at an intracellular site, and involves both
channel shut down (Kd = 4-5 M) and a reduction of γ (Kd = 13-
14 M). Blockade of channel activity by SITS, DIDS, Gd3+ and
arachidonic acid is paralleled by decreased swelling-induced re-
lease of ATP [23, 83]. Channel activation by anti-oestrogens in
whole cell recordings requires the presence of intracellular nu-
cleotides and is prevented by pre-treatment with 17β-estradiol,
bucladesine, or intracellular dialysis with GDPβS [20]. Activation
by tamoxifen is suppressed by low concentrations of okadaic acid,
suggesting that a dephosphorylation event by protein phos-
phatase PP2A occurs in the activation pathway [20]. In contrast,
17β-estradiol and tamoxifen appear to directly inhibit the maxi
Cl- channel of human placenta reconstituted into giant liposomes
and recorded in excised patches [80].
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Volume regulated chloride channels
Other ion channels! Chloride channels! Volume regulated chloride channels
Overview: Volume activated chloride channels (also termed
VSOAC, volume-sensitive organic osmolyte/anion channel; VRC,
volume regulated channel and VSOR, volume expansion-sensing
outwardly rectifying anion channel) participate in regulatory vol-
ume decrease (RVD) in response to cell swelling. VRAC may also
be important for several other processes including the regulation
of membrane excitability, transcellular Cl- transport, angiogene-
sis, cell proliferation, necrosis, apoptosis, glutamate release from
astrocytes, insulin ( INS, P01308) release from pancreatic β cells
and resistance to the anti-cancer drug, cisplatin (reviewed by [10,
60, 63, 66]). VRAC may not be a single entity, but may instead
represent a number of different channels that are expressed to a
variable extent in different tissues and are differentially activated
by cell swelling. In addition to ClC-3 expression products (see
above) several former VRAC candidates including MDR1 (ABCB1,
P-glycoprotein), Icln, Band 3 anion exchanger (SLC4A1) and phos-
pholemman are also no longer considered likely to fulfil this func-
tion (see reviews [63, 86]).
Nomenclature VRAC
Functional Characteristics γ = 10-20 pS (negative potentials), 50-90 pS (positive potentials); permeability sequence SCN > I > NO3- >Br
-
> Cl- > F- > gluconate; outward
rectification due to voltage dependence of γ; inactivates at positive potentials in many, but not all, cell types; time dependent inactivation at
positive potentials; intracellular ionic strength modulates sensitivity to cell swelling and rate of channel activation; rate of swelling-induced
activation is modulated by intracellular ATP concentration; ATP dependence is independent of hydrolysis and modulated by rate of cell swelling;
inhibited by increased intracellular free Mg2+ concentration; swelling induced activation of several intracellular signalling cascades may be
permissive of, but not essential to, the activation of VRAC including: the Rho-Rho kinase-MLCK; Ras-Raf-MEK-ERK; PIK3-NOX-H2O2 and
Src-PLCγ-Ca2+ pathways; regulation by PKCα required for optimal activity; cholesterol depletion enhances activity; activated by direct stretch of
β1-integrin
Activators GTPγS
Endogenous channel blockers intracellular Mg2+, arachidonic acid
Channel blockers 1,9-dideoxyforskolin, 9-anthroic acid, DCPIB, DIDS, IAA-94, NPPB, NS3728, carbenoxolone, clomiphene, diBA-(5)-C4, gossypol, mefloquine,
mibefradil, nafoxidine, nordihydroguiaretic acid, quinidine, quinine, tamoxifen
Comments VRAC is also activated by cell swelling and low intracellular ionic strength. VRAC is also blocked by chromones, extracellular nucleotides and
nucleoside analogues
Comments: In addition to conducting monovalent anions, in many cell types the activation of VRAC by a hypotonic stimulus can allow the efflux of organic osmolytes such as amino acids and polyols
that may contribute to RVD.
Comments: Other chloride channels
In addition to some intracellular chloride channels that are not
considered here, plasma membrane channels other than those
listed have been functionally described. Many cells and tis-
sues contain outwardly rectifying chloride channels (ORCC) that
may correspond to VRAC active under isotonic conditions. A
cyclic AMP-activated Cl- channel that does not correspond to
CFTR has been described in intestinal Paneth cells [100]. A Cl
channel activated by cyclic GMP with a dependence on raised in-
tracellular Ca2+ has been recorded in various vascular smooth
muscle cells types, which has a pharmacology and biophysi-
cal characteristics very different from the ‘conventional’ CaCC
[56, 75]. It has been proposed that bestrophin-3 ( BEST3,
Q8N1M1) is an essential component of the cyclic GMP-activated
channel [57]. A proton-activated, outwardly rectifying anion
channel has also been described [44].
Searchable database: http://www.guidetopharmacology.org/index.jsp Volume regulated chloride channels 5950
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13351/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels. British Journal of Pharmacology (2015) 172, 5942–5955
Further Reading
Accardi A et al. (2010) CLC channels and transporters: proteins with borderline personalities.
Biochim. Biophys. Acta 1798: 1457-64 [PMID:20188062]
Alekov AK et al. (2008) Anion channels: regulation of ClC-3 by an orphan second messenger. Curr.
Biol. 18: R1061-4 [PMID:19036336]
Aleksandrov AA et al. (2007) CFTR (ABCC7) is a hydrolyzable-ligand-gated channel. Pflugers Arch.
453: 693-702 [PMID:17021796]
Amaral MD et al. (2007) Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis.
Trends Pharmacol. Sci. 28: 334-41 [PMID:17573123]
Aromataris EC et al. (2006) ClC-1 chloride channel: Matching its properties to a role in skeletal
muscle. Clin. Exp. Pharmacol. Physiol. 33: 1118-23 [PMID:17042925]
Ashlock MA et al. (2011) Therapeutics development for cystic fibrosis: a successful model for a mul-
tisystem genetic disease. Annu. Rev. Med. 62: 107-25 [PMID:21226613]
Best L et al. (2010) Electrical activity in pancreatic islet cells: The VRAC hypothesis. Islets 2: 59-64
[PMID:21099297]
Chen TY. (2005) Structure and function of clc channels. Annu. Rev. Physiol. 67: 809-39
[PMID:15709979]
Chen TY et al. (2008) CLC-0 and CFTR: chloride channels evolved from transporters. Physiol. Rev.
88: 351-87 [PMID:18391167]
Cuthbert AW. (2011) New horizons in the treatment of cystic fibrosis. Br. J. Pharmacol. 163: 173-83
[PMID:21108631]
Duan D. (2009) Phenomics of cardiac chloride channels: the systematic study of chloride channel
function in the heart. J. Physiol. (Lond.) 587: 2163-77 [PMID:19171656]
Duan DD. (2011) The ClC-3 chloride channels in cardiovascular disease. Acta Pharmacol. Sin. 32:
675-84 [PMID:21602838]
Duran C et al. (2011) Physiological roles and diseases of Tmem16/Anoctamin proteins: are they all
chloride channels? Acta Pharmacol. Sin. 32: 685-92 [PMID:21642943]
Duran C et al. (2010) Chloride channels: often enigmatic, rarely predictable. Annu. Rev. Physiol. 72:
95-121 [PMID:19827947]
Dutzler R. (2007) A structural perspective on ClC channel and transporter function. FEBS Lett. 581:
2839-44 [PMID:17452037]
Edwards JC et al. (2010) Chloride channels of intracellular membranes. FEBS Lett. 584: 2102-11
[PMID:20100480]
Fahlke C et al. (2010) Physiology and pathophysiology of ClC-K/barttin channels. Front Physiol 1:
155 [PMID:21423394]
Ferrera L et al. (2010) TMEM16A protein: a new identity for Ca(2+)-dependent Cl  channels. Physi-
ology (Bethesda) 25: 357-63 [PMID:21186280]
GadsbyDC et al. (2006) The ABC protein turned chloride channel whose failure causes cystic fibrosis.
Nature 440: 477-83 [PMID:16554808]
Galietta LJ. (2009) The TMEM16 protein family: a new class of chloride channels? Biophys. J. 97:
3047-53 [PMID:20006941]
Greenwood IA et al. (2007) Overlapping pharmacology of Ca2+-activated Cl- and K+ channels. Trends
Pharmacol. Sci. 28: 1-5 [PMID:17150263]
Guan YY et al. (2006) The ClC-3 Cl- channel in cell volume regulation, proliferation and apoptosis
in vascular smooth muscle cells. Trends Pharmacol. Sci. 27: 290-6 [PMID:16697056]
Hartzell C et al. (2005) Calcium-activated chloride channels. Annu. Rev. Physiol. 67: 719-58
[PMID:15709976]
Hartzell HC et al. (2008) Molecular physiology of bestrophins: multifunctional membrane proteins
linked to best disease and other retinopathies. Physiol. Rev. 88: 639-72 [PMID:18391176]
Jentsch TJ. (2008) CLC chloride channels and transporters: from genes to protein structure, pathol-
ogy and physiology. Crit. Rev. Biochem. Mol. Biol. 43: 3-36 [PMID:18307107]
Kirk KL et al. (2011) A unified view of cystic fibrosis transmembrane conductance regulator (CFTR)
gating: combining the allosterism of a ligand-gated channel with the enzymatic activity of an
ATP-binding cassette (ABC) transporter. J. Biol. Chem. 286: 12813-9 [PMID:21296873]
Krämer BK et al. (2008) Mechanisms of Disease: the kidney-specific chloride channels ClCKA
and ClCKB, the Barttin subunit, and their clinical relevance. Nat Clin Pract Nephrol 4: 38-46
[PMID:18094726]
Kunzelmann K et al. (2011) Anoctamins. Pflugers Arch. 462: 195-208 [PMID:21607626]
Leblanc N et al. (2005) Regulation of calcium-activated chloride channels in smooth muscle cells: a
complex picture is emerging. Can. J. Physiol. Pharmacol. 83: 541-56 [PMID:16091780]
Muallem D et al. (2009) Review. ATP hydrolysis-driven gating in cystic fibrosis transmembrane con-
ductance regulator. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 364: 247-55 [PMID:18957373]
Mulligan SJ et al. (2006) VRACs CARVe a path for novel mechanisms of communication in the CNS.
Sci. STKE 2006: pe42 [PMID:17047222]
Noy E et al. (2011) Combating cystic fibrosis: in search for CF transmembrane conductance regulator
(CFTR) modulators. ChemMedChem 6: 243-51 [PMID:21275046]
Okada Y. (2006) Cell volume-sensitive chloride channels: phenotypic properties andmolecular iden-
tity. Contrib Nephrol 152: 9-24 [PMID:17065805]
Okada Y et al. (2009) Pathophysiology and puzzles of the volume-sensitive outwardly rectifying
anion channel. J. Physiol. (Lond.) 587: 2141-9 [PMID:19171657]
Patel AC et al. (2009) The role of CLCA proteins in inflammatory airway disease. Annu. Rev. Physiol.
71: 425-49 [PMID:18954282]
Planells-Cases R et al. (2009) Chloride channelopathies. Biochim. Biophys. Acta 1792: 173-89
[PMID:19708126]
Plans V et al. (2009) Physiological roles of CLC Cl(-)/H (+) exchangers in renal proximal tubules.
Pflugers Arch. 458: 23-37 [PMID:18853181]
Puljak L et al. (2006) Emerging roles of chloride channels in human diseases. Biochim. Biophys. Acta
1762: 404-13 [PMID:16457993]
Pusch M et al. (2006) Channel or transporter? The CLC saga continues. Exp. Physiol. 91: 149-52
[PMID:16179405]
Riordan JR. (2005) Assembly of functional CFTR chloride channels. Annu. Rev. Physiol. 67: 701-18
[PMID:15709975]
Riquelme G. (2009) Placental chloride channels: a review. Placenta 30: 659-69 [PMID:19604577]
Sabirov RZ et al. (2009) The maxi-anion channel: a classical channel playing novel roles through an
unidentified molecular entity. J Physiol Sci 59: 3-21 [PMID:19340557]
Sloane PA et al. (2010) Cystic fibrosis transmembrane conductance regulator protein repair as a ther-
apeutic strategy in cystic fibrosis. Curr Opin Pulm Med 16: 591-7 [PMID:20829696]
Verkman AS et al. (2009) Chloride channels as drug targets. Nat Rev Drug Discov 8: 153-71
[PMID:19153558]
Searchable database: http://www.guidetopharmacology.org/index.jsp Volume regulated chloride channels 5951
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13351/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels. British Journal of Pharmacology (2015) 172, 5942–5955
Connexins and Pannexins
Other ion channels! Connexins and Pannexins
Overview: Gap junctions are essential for many physiological
processes including cardiac and smooth muscle contraction, regu-
lation of neuronal excitability and epithelial electrolyte transport
[13, 17, 28]. Gap junction channels allow the passive diffusion
of molecules of up to 1,000 Daltons which can include nutrients,
metabolites and second messengers (such as IP3) as well as cations
and anions. 21 connexin genes and 3 pannexin genes (which
are structurally related to the invertebrate innexin genes) code
for gap junction proteins in humans. Each connexin gap junc-
tion comprises 2 hemichannels or ‘connexons’ which are them-
selves formed from 6 connexin molecules. The various connexins
have been observed to combine into both homomeric and het-
eromeric combinations, each of which may exhibit different func-
tional properties. It is also suggested that individual hemichannels
formed by a number of different connexins might be functional in
at least some cells [39]. Connexins have a common topology, with
four α-helical transmembrane domains, two extracellular loops, a
cytoplasmic loop, and N- and C-termini located on the cytoplas-
mic membrane face. In mice, the most abundant connexins in
electrical synapses in the brain seem to be Cx36, Cx45 and Cx57
[97]. Mutations in connexin genes are associated with the occur-
rence of a number of pathologies, such as peripheral neuropathies,
cardiovascular diseases and hereditary deafness. The pannexin
genes Px1 and Px2 are widely expressed in the mammalian brain
[102]. Like the connexins, at least some of the pannexins can form
hemichannels [13, 72].
Nomenclature Cx23 Cx25 Cx26 Cx30 Cx30.2
HGNC, UniProt GJE1, A6NN92 GJB7, Q6PEY0 GJB2, P29033 GJB6, O95452 GJC3, Q8NFK1
Endogenous inhibitors extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, flufenamic acid, octanol
Nomenclature Cx30.3 Cx31 Cx31.1 Cx31.9 Cx32
HGNC, UniProt GJB4, Q9NTQ9 GJB3, O75712 GJB5, O95377 GJD3, Q8N144 GJB1, P08034
Endogenous inhibitors extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, flufenamic acid, octanol
Nomenclature Cx36 Cx37 Cx40 Cx40.1 Cx43
HGNC, UniProt GJD2, Q9UKL4 GJA4, P35212 GJA5, P36382 GJD4, Q96KN9 GJA1, P17302
Endogenous inhibitors extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, flufenamic acid, octanol
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Nomenclature Cx45 Cx46 Cx47 Cx50 Cx59 Cx62
HGNC, UniProt GJC1, P36383 GJA3, Q9Y6H8 GJC2, Q5T442 GJA8, P48165 GJA9, P57773 GJA10, Q969M2
Endogenous inhibitors extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, flufenamic acid, octanol
Nomenclature Px1 Px2 Px3
HGNC, UniProt PANX1, Q96RD7 PANX2, Q96RD6 PANX3, Q96QZ0
Endogenous inhibitors – – –
Inhibitors carbenoxolone, flufenamic acid (little block by flufenamic acid)
Comments Px1 is unaffected by raising external Ca2+, Px2 is unaffected by raising external Ca2+, Px3 is unaffected by raising external Ca2+
Comments: Connexins are most commonly named according
to their molecular weights, so, for example, Cx23 is the connexin
protein of 23 kDa. This can cause confusion when comparing be-
tween species - for example, the mouse connexin Cx57 is orthol-
ogous to the human connexin Cx62. No natural toxin or specific
inhibitor of junctional channels has been identified yet however
two compounds often used experimentally to block connexins are
carbenoxolone and flufenamic acid [85]. At least some pannexin
hemichannels are more sensitive to carbenoxolone than connex-
ins but much less sensitive to flufenamic acid [12]. It has been
suggested that 2-aminoethoxydiphenyl borate (2-APB) may be a
more effective blocker of some connexin channel subtypes (Cx26,
Cx30, Cx36, Cx40, Cx45, Cx50) compared to others (Cx32, Cx43,
Cx46, [8]).
Further Reading
Cruciani V et al. (2006) The vertebrate connexin family. Cell. Mol. Life Sci. 63: 1125-40
[PMID:16568237]
Evans WH et al. (2006) The gap junction cellular internet: connexin hemichannels enter the sig-
nalling limelight. Biochem. J. 397: 1-14 [PMID:16761954]
Kandouz M et al. (2010) Gap junctions and connexins as therapeutic targets in cancer. Expert Opin.
Ther. Targets 14: 681-92 [PMID:20446866]
MacVicar BA et al. (2010) Non-junction functions of pannexin-1 channels. Trends Neurosci. 33:
93-102 [PMID:20022389]
Mese G et al. (2007) Gap junctions: basic structure and function. J. Invest. Dermatol. 127: 2516-24
[PMID:17934503]
Shestopalov VI et al. (2008) Pannexins and gap junction protein diversity. Cell. Mol. Life Sci. 65:
376-94 [PMID:17982731]
Söhl G et al. (2005) Expression and functions of neuronal gap junctions. Nat. Rev. Neurosci. 6:
191-200 [PMID:15738956]
Zoidl G et al. (2010) Gap junctions in inherited human disease. Pflugers Arch. 460: 451-66
[PMID:20140684]
Searchable database: http://www.guidetopharmacology.org/index.jsp Connexins and Pannexins 5953
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13351/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels. British Journal of Pharmacology (2015) 172, 5942–5955
Sodium leak channel, non-selective
Other ion channels! Sodium leak channel, non-selective
Overview: The sodium leak channel, non selective
(NC-IUPHAR tentatively recommends the nomencla-
ture NaVi2.1, W.A. Catterall, personal communication)
is structurally a member of the family of voltage-gated sodium
channel family (Nav1.1 - Nav1.9) [47, 107]. In contrast to the
latter, NaVi2.1, is voltage-insensitive (denoted in the subscript
‘vi’ in the tentative nomenclature) and possesses distinctive ion
selectivity and pharmacological properties. NaVi2.1, which is
insensitive to tetrodotoxin (10 M), has been proposed to me-
diate the tetrodotoxin-resistant and voltage-insensitive Na+ leak
current (IL-Na) observed in many types of neurone [52]. However,
whether NaVi2.1 is constitutively active has been challenged [96].
NaVi2.1 is widely distributed within the central nervous system
and is also expressed in the heart and pancreas specifically, in
rodents, within the islets of Langerhans [47, 52].
Nomenclature Navi2.1
HGNC, UniProt NALCN, Q8IZF0
Activators Constitutively active (Lu et al., 2007), or activated downstream of Src family tyrosine kinases (SFKs) (Lu et al.,2009; Swayne et al., 2009); positively modulated by
decreased extracellular Ca2+ concentration (Lu et al., 2010) [52, 53, 54, 96]
Functional Characteristics γ = 27 pS (by fluctuation analysis), PNa/PCs = 1.3, PK/PCs = 1.2, PCa/PCs = 0.5, linear current voltage-relationship, voltage-independent and non-inactivating
Channel blockers Gd3+ (pIC50 5.6), Cd
2+ (pIC50 3.8), Co
2+ (pIC50 3.6), verapamil (pIC50 3.4)
Comments: In native and recombinant expression systems
NaVi2.1 can be activated by stimulation of NK1 (in hippocam-
pal neurones), neurotensin (in ventral tegmental area neurones)
andM3muscarinic acetylcholine receptors (in MIN6 pancreatic β-
cells) and in a manner that is independent of signalling through
G-proteins [53, 96]. Pharmacological andmolecular biological evi-
dence indicates such modulation to occur though a pathway that
involves the activation of Src family tyrosine kinases. It is sug-
gested that NaVi2.1 exists as a macromolecular complex with M3
receptors [96] and peptide receptors [53], in the latter instance in
association with the protein UNC-80, which recruits Src to the
channel complex [53, 103]. By contrast, stimulation of Navi2.1
by decreased extracellular Ca2+ concentration is G-protein de-
pendent and involves a Ca2+-sensing G protein-coupled recep-
tor and UNC80 which links Navi2.1 to the protein UNC79 in
the same complex [54]. NaVi2.1 null mutant mice have severe
disturbances in respiratory rhythm and die within 24 hours of
birth [52]. Navi2.1 heterozygous knockout mice display increased
serum sodium concentrations in comparison to wildtype litter-
mates and a role for the channel in osmoregulation has been pos-
tulated [92].
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